SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

URGN

UroGen Pharma Ltd.
BEARISH
Impact 6/10
Horizonweeks Processed12d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and JELMYTO guidance cut are the primary negatives, partially offset by ZUSDURI growth and UGN-103 NDA acceptance. Watch for UGN-103 PDUFA decision in June 2027 and any updates on the LONGVIEW-HR trial initiation.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$28.74
T+0 close · Nov 4, 2026 · via day close
Latest settled
−9.19%
T+5 · $26.10 · next T+20 in 16d
Vs SPY
−8.27%
α at T+5
Latest observation
+0.16%
T+8 · FF3 residual α
  1. T+0 · Nov 4 $28.74entry
  2. T+1 · 12d ago −10.47%α −6.06% · $25.73
  3. T+5 · 6d ago −9.19%α −8.27% · $26.10
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ZUSDURI revenue grew 35% QoQ to $68.0M, but JELMYTO revenue declined to $21.0M and full-year JELMYTO guidance was lowered to ~$90M from $97-101M. The FDA accepted the UGN-103 NDA with a PDUFA date of June 14, 2027.

Key Financial Metrics

Revenue
$89.0M
est $89.9M · -1.0% · +223.8% YoY
Guidance
~$90M (JELMYTO only)
lowered
Gross Margin
91.6%

Key Facts

  • Total revenue $89.0M vs. $89.9M consensus (slight miss)
  • ZUSDURI net product revenue $68.0M, up 35% QoQ
  • JELMYTO net product revenue $21.0M, down from $25.7M YoY
  • Full-year 2026 JELMYTO revenue guidance lowered to ~$90M from $97-101M
  • FDA accepted UGN-103 NDA; PDUFA date June 14, 2027
  • Net loss narrowed to $1.5M from $33.3M YoY
  • Cash and equivalents $90.5M as of Sep 30, 2026

Financial Impact

EPS miss of $0.13 vs consensus; JELMYTO guidance cut by $7-11M; net loss improved by $31.8M YoY

epsrevenueguidance

Segment Breakdown

SegmentRevenueGrowth
ZUSDURI$68.0M+35.0%
JELMYTO$21.0M-18.3%

Risk Factors

  • JELMYTO revenue decline due to competitive trial enrollment and CMS adjustments
  • UGN-103 approval uncertainty despite NDA acceptance
  • Cash burn rate; $90.5M may require future financing
  • Shareholders' deficit of $125M

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395238

Track record

16 reports on URGN

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Viewing Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026